RxDoctor Payments Data

Monique Brunelle, APRN

Family · Bolton, CTNPI 1770368532

Payments from drug & device makers

$3,488in general payments, 2019–2025

Across 149 payments — averaging $23.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$790
  • Novo Nordisk$722
  • Lilly USA, LLC$379
  • AbbVie$302
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$249
  • Boehringer Ingelheim$171
  • plus $875 from 13 others

What the payments were for

  • Food & beverage$3,42198%
  • Education$682%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,488 in reported general payments places this provider in the 85th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$18,378
Medicare patients
72
Services billed
209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin17$24,617
RybelsusSemaglutide14$19,478
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,272
Tramadol Hcl33$1,239
Levothyroxine Sodium150$987
Duloxetine Hcl27$956
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid12$855
Albuterol Sulfate HfaAlbuterol Sulfate29$683
Bupropion XlBupropion Hcl26$622
Oxycodone Hcl17$535
Atorvastatin Calcium61$499
Oxybutynin Chloride ErOxybutynin Chloride13$476
Lisinopril65$463
Famotidine16$425
Diclofenac Sodium14$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$171$24,61717 claims
Novo NordiskRybelsus$722$19,47814 claims
AstraZenecaBreztri Aerosphere$790$11,27218 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$141$987150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,596 family providers in Connecticut.

Other family in Bolton

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →